Efficacy of Agomelatine in Depressive Disorders with Anxiety

Pribytkov, A. A.; Panova, N. B.; Popova, Yulia V.; Emtsov, K. G.

doi:10.1007/s11055-015-0087-7

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sleep changes shown here are also consistent with agomelatine studies in depression (Poluéktov and Levin, 2013; Pribytkov et al, 2013). The increase in TST resulting from agomelatine treatment, according to ACM recordings, has been described in adults with major depressive disorder using polysomnography (Poluéktov and Levin, 2013; Pribytkov et al, 2013). TST was also increased following agomelatine treatment in a larger study (Quera-Salva et al, 2011) that compared agomelatine against escitalopram using polysomnography.…”

Section: Discussionsupporting

confidence: 90%

“…risperidone) for autistic symptoms has indirectly improved participants' sleep performance (Gvozdjáková et al, 2014;Kent et al, 2013). Sleep changes shown here are also consistent with agomelatine studies in depression (Poluéktov and Levin, 2013;Pribytkov et al, 2013). The increase in TST resulting from agomelatine treatment, according to ACM recordings, has been described in adults with major depressive disorder using polysomnography (Poluéktov and Levin, 2013;Pribytkov et al, 2013).…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability

et al. 2019

View full text Add to dashboard Cite

Purpose: Intellectual disability (ID) and autism spectrum disorder (ASD) are common, co-occurring developmental disorders and are frequently associated with sleep problems. This study aimed to assess the effectiveness and tolerability of agomelatine as a pharmacotherapy for sleep problems in ASD adults with ID. Method: A randomised, crossover, triple-blind, placebo-controlled clinical trial, with two three-month periods of treatment starting with either agomelatine or placebo and a washout period of two weeks. Ambulatory circadian monitoring (24 hours/7 days) evaluated total sleep time (TST) as the primary outcome variable. Results: Participants ( N=23; 35±12 years old; 83% male) had a median of three (interquartile range (IQR) 1–4) co-morbidities and were taking a median of five (IQR 2–7) prescribed drugs. Before agomelatine or placebo treatment, all subjects presented with insomnia symptoms, including sleep latency (100% abnormal, 55±23 minutes) or TST (55% abnormal, 449±177 minutes), and 66% had circadian rhythm sleep–wake abnormalities with rhythm phase advancements according to the M5 sleep phase marker values. During the three-month agomelatine treatment, night TST significantly increased by a mean of 83 minutes (16% abnormal, 532±121 minutes), together with a phase correction (M5 1:45±2:28 hours vs. 3:15±2:20 hours), improving sleep stability in wrist temperature rhythm (0.43±0.29 vs. 0.52±0.18 AU). Adverse events were mild and transient. Conclusions: Agomelatine was effective and well tolerated for treating insomnia and circadian rhythm sleep problems present in adults with ASD and ID.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 83%

Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability

et al. 2019

View full text Add to dashboard Cite

show abstract

Agomelatine: An Astounding Sui-generis Antidepressant?

Naveed

Sheng

et al. 2022

CMP

View full text Add to dashboard Cite

: Major depressive disorder (MDD) is one of the foremost causes of disability and premature death worldwide. Although the available antidepressants are effective and well tolerated, they also have many limitations. Therapeutic advances in developing a new drug's ultimate relation between MDD and chronobiology, which targets the circadian rhythm, have led to a renewed focus on psychiatric disorders. In order to provide a critical analysis about antidepressant properties of agomelatine, a detailed PubMed (Medline), Scopus (Embase), Web of Science (Web of Knowledge), Cochrane Library, Google Scholar, and PsycInfo search was performed using the following keywords: melatonin analog, agomelatine, safety, efficacy, adverse effects, pharmacokinetics, pharmacodynamics, circadian rhythm, sleep disorders, neuroplasticity, MDD, bipolar disorder, anhedonia, anxiety, generalized anxiety disorder (GAD), and mood disorders. Agomelatine is a unique melatonin analog with antidepressant properties and a large therapeutic index that improves clinical safety. It is a melatonin receptor agonist (MT1 and MT2) and a 5-HT2C receptor antagonist. The effects on melatonin receptors enable the resynchronization of irregular circadian rhythms with beneficial effects on sleep architectures. In this way, agomelatine is accredited for its unique mode of action, which helps to exert antidepressant effects and resynchronize the sleep-wake cycle. To sum up, an agomelatine has not only antidepressant properties but also has anxiolytic effects.

show abstract

Efficacy of Agomelatine in Depressive Disorders with Anxiety

Cited by 2 publications

References 30 publications

Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability

Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability

Agomelatine: An Astounding Sui-generis Antidepressant?

Contact Info

Product

Resources

About